Prestige Consumer Healthcare markets a portfolio of well-known over-the-counter brands across categories such as eye care, oral care, dermatology, women’s health, and gastrointestinal relief. Flagship names include Clear Eyes, Dramamine, Compound W, Monistat, Summer’s Eve, Luden’s, and BC/Goody’s pain powders. The business model centers on acquiring, defending, and growing established consumer brands with strong retail distribution rather than running a large R&D pipeline of novel drugs. Customers are mainly mass-market shoppers reached through drugstores, grocery, and e-commerce in North America and selected international markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 296.5 | — | 50.1 | -1% |
| Q2 2025 | 249.5 | — | 47.5 | 5.7% |
| Q3 2025 | 274.1 | — | 42.2 | -21.9% |
| Q4 2025 | 283.4 | — | 46.7 | -22.5% |
| Q1 2026 | 281.6 | -5% | 53.9 | 7.6% |
| Q2 2026 | 265.7 | 6.5% | 29.2 | -38.5% |
All markets — KeepWinning global stock screener
Other companies on NYSE: LCI Industries (LCII), StubHub Holdings, Inc. (STUB), V2X, Inc. (VVX), Boyd Group Services Inc. (BGSI), Helios Technologies, Inc. (HLIO), Cadeler A/S (CDLR)